Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Säkerhets- och effektivitetsutvärdering av autologa CRISPR-Cas12b-redigerade hematopoetiska stamceller

2 november 2026 uppdaterad av: Jun Shi, Institute of Hematology & Blood Diseases Hospital, China

En studie för att utvärdera effektiviteten och säkerheten hos autologa CRISPR-Cas12b-redigerade hematopoetiska stamceller hos transfusionsberoende β-talassemipatienter

This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

Through CRISPR-Cas 12b editing tool with independent intellectual property rights of Chinese Academy of Sciences, HBG1/2 promoter was edited to reactivate gamma-globin and induce fetal hemoglobin (HbF) expression. This leads to a subsequent reduction in ineffective red blood cell production (due to a reduction in the uncompounded alpha-globin chain) and improved red blood cell survival (due to reduced hemolysis), ultimately improving the sequelae of anemia and reducing the need for transfusion. Safety and efficacy will be evaluated continuously throughout the study, follow-up was up to 24 months. After the end of this trial, participants who received the infusion of autologous CRISPR-Cas12b edited hematopoietic stem cells (VGB-Ex01) will be invited to participate in the long-term follow-up study to complete the 15-year follow-up plan.

Studietyp

Interventionell

Inskrivning (Faktisk)

1

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina
        • Regenerative Medicine Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

3 år till 35 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 3-35 years old (inclusive), male or female;
  • The subject and/or his/her legally recognized representative/parent/guardian fully understands the study and all information related to the study and has signed the informed consent form;
  • Clinical diagnosis of transfusion-dependent β-thalassemia (TDT) with a blood transfusion record within 2 years (inclusive) prior to screening showing a history of ≥ 10 units (U)/kg/year (or ≥ 100 mL/kg/year) or ≥ 8 times/year of suspended RBC transfusions in at least 1 consecutive 12-month period;
  • Karnofsky score (for subjects aged ≥ 16 years) or Lansky score (for subjects aged < 16 years) of ≥ 80;
  • Subjects in stable disease state who are eligible for hematopoietic stem cell transplantation as per investigator's judgment;
  • Access to diagnosis and treatment records issued by medical professional institutions within 2 years prior to screening, including the records of blood transfusions, hematology, serum chemistry, and other examinations;
  • Willing and able to comply with study procedures, with good compliance, and willing to receive and complete the follow-up study with a duration of at least 2 years;
  • Subjects of childbearing potential (including female subjects of childbearing potential and male subjects whose partners are of childbearing potential) must use effective contraception within 12 months of treatment.

Exclusion Criteria:

  • Diagnosis of associated α-thalassemia: > 1 alpha chain deletion or alpha gene functional defect;
  • Have available HLA-fully matched donors and acceptable for allogeneic hematopoietic stem cell transplantation;
  • Irregular antibody or platelet antibody positive;
  • Prior allogeneic bone marrow transplantation or gene therapy;
  • Subjects with clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator at screening, including but not limited to those with positive etiology of human immunodeficiency virus (HIV-1/2), human cytomegalovirus (HCMV-DNA), Epstein-Barr virus (EBV-DNA), or Treponema pallidum antibody (TP-Ab), or with previous hepatitis B or C infection;
  • Subjects with an injury of major organs
  • Contraindications for hematopoietic stem cell collection and poor collection efficiency judged by the investigator;
  • Contraindications to the clinical investigational product and its excipients, G-CSF (hematopoietic stem cell mobilization), plerixafor (hematopoietic stem cell mobilization), busulfan (myeloablation), and other drugs;
  • Participation within 3 months prior to screening or current participation in another interventional clinical study;
  • History or family history of malignancy or myeloproliferative disorder;
  • History of uncontrollable epilepsy, mental disorder, or other psychiatric disorders;
  • Abuse of psychoactive substance, drug, or alcohol within 6 months prior to enrollment;
  • Pregnant or breastfeeding females;
  • Other diseases or reasons that interfere with study procedures;
  • Any other conditions that the investigator deems unsuitable for the subject's participation in the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: VGB-Ex01

Each subject will accept one dose of VGB-Ex01.

CRISPR-Cas12b editing hematopoietic stem cells

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of adverse events and serious adverse events
Tidsram: Baseline up to 24 months

An adverse event is any untoward medical occurrence in a clinical investigation/participant administered a product; the event will not need to have a causal relationship with the treatment. A serious adverse event is any untoward medical occurrence at any dose that resulted in death; life threatening;require inpatient hospitalization or prolongation of existing hospitalization; result in persistent or significant disability/incapacity; result in congenital anomaly/birth defect.

Baseline up to 24 months
Number of subjects with neutrophil implantation ≤ 42 days
Tidsram: Baseline up to 42 days

Neutrophil implantation was defined as 3 consecutive days with 3 tests for ANC≥500/μL.

Baseline up to 42 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of subjects transfusion independence (TI) for at least 6 months after transfusion
Tidsram: Baseline up to 6 months

TI defined as Hb≥9g/dL without red blood cell infusion

Baseline up to 6 months
Number of subjects transfusion independence (TI) for at least 12 months after transfusion
Tidsram: Baseline up to 12 months

TI defined as Hb≥9g/dL without red blood cell infusion

Baseline up to 12 months
Fetal hemoglobin (HbF) concentration
Tidsram: Baseline up to 24 months

Changes in HbF concentration from baseline after transfusion

Baseline up to 24 months
Total hemoglobin (Hb) concentration
Tidsram: Baseline up to 24 months

Changes in Hb concentration compared with baseline after transfusion

Baseline up to 24 months
The proportion of circulating red blood cells
Tidsram: Baseline up to 24 months

Changes in the proportion of circulating red blood cells expressing fetal hemoglobin compared to baseline

Baseline up to 24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jun Shi, PhD, Institute of Hematology & Blood Diseases Hospital, China

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

31 augusti 2023

Primärt slutförande (Faktisk)

31 december 2023

Avslutad studie (Faktisk)

31 december 2023

Studieregistreringsdatum

Först inskickad

11 september 2023

Först inskickad som uppfyllde QC-kriterierna

11 september 2023

Första postat (Faktisk)

18 september 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera